China Pharma Holdings Falls 35.88% Since April 17, Now Trading at PE of 4.3x

According to Zhitong Finance, China Pharma Holdings (00013) stock declined 35.88% since April 17, 2026, hitting a low of 15.57 HKD on June 22, significantly outpacing the 27.65% drop in the Hang Seng Healthcare Index over the same period. The plunge reflects broader portfolio rebalancing as funds rotated toward artificial intelligence sectors, compounded by short-selling pressure that surged from 9.27% to 25.92% in mid-April.

Current valuation presents a contrasting picture: the company trades at a PE of just 4.3x, 81% below the sector average of 22.28x, signaling deep oversold conditions. Concurrently, offshore capital flows shifted strategy in late May from accumulation to active reduction, yet 2025 fiscal results showed tumor-related revenue of 115 million USD, up 16.4% sequentially, with management projecting 2026 tumor revenue of 330-450 million USD, representing 15.6%-57.6% year-over-year growth.